



Breast Cancer

Syndicated Thought Leader Insight

Thought Leader Insight & Analysis Report **Breast Cancer Q1 2010**

Therapeutic Class:	Oncology
Focus Area:	Breast Cancer
Specialty/Location:	Oncologists / N. America, Europe
Number of Interviews:	6
Number of Pages:	143
Publication Date:	March 2010
Principal Authors:	Kim Grant Tricia L. Hanlon Jeffrey D. Berk, Ph.D., MBA
Product Code:	MHOBCQ110-24
Pricing:	\$7,500
Order Info:	www.medpredict.com or call (513) 271-1924

Abstract:

In this report, the 24th in our Oncology series, we summarize the perspectives of six world-class experts in the treatment of breast cancer. In this report they provide their opinions on standards of care today and their expectations for experimental therapeutics. The Panel deals with a number of issues that are important to companies trying to differentiate their new drugs within a very crowded space, including strategies and clinical trial designs that will help to leapfrog more advanced competitors. They reveal the key indications worth pursuing, and the classes of drugs that can produce meaningful survival advantages for women with these breast cancers.

This report provides essential KOL insight for key stakeholders in the breast cancer market at a significant value versus customized primary research.

Pharmacotherapies/Companies Discussed in This Report (Alphabetical by Target):

Angiogenesis inhibitors (VEGF / PDGF / FGF / VDA)

Avastin; bevacizumab (Genentech)
Nexavar; sorafenib (Bayer-Schering/Onyx)
Sutent; sunitinib (Pfizer)

Antiresorptives

Bonefos; clodronate (Bayer-Schering)
Prolia; denosumab (Amgen)
Zometa; zoledronic acid (Novartis)

Antimitotics

Eribulin; E7389 (Eisai)
Ixempra; ixabepilone (Bristol-Myers Squibb)
Abraxane; nab-paclitaxel (Abraxis)
Xeloda; capecitabine (Roche)
Xyotax; a.k.a. Opaxio (Cell Therapeutics)

Bcl2

ABT-737 (Abbott)

glycoprotein NMB (GPNMB)

CDX-011; CR011-vcMMAE (Celldex)

HER2

Herceptin; trastuzumab (Genentech)
Omnitarg; pertuzumab (Genentech)
trastuzumab-DM1 (Genentech / ImmunoGen)

HER2/EGFR

Tykerb; lapatinib (GlaxoSmithKline)
neratinib; HKI-272 (Pfizer)

HER3

MM-121 (Sanofi-Aventis / Merrimack)

IGF1

AMG 479 (Amgen)
dalotuzumab; MK-0646 (Merck)
figitumumab; CP-751871 (Pfizer)

MEK

1120212 (GlaxoSmithKline)

PARP

ABT-888 (Abbott)
AG014699 (Pfizer)
BSI-201 (BiPar / Sanofi-Aventis)
MK-4827 (Merck)
olaparib; AZD2281 (AstraZeneca)

PI3K / mTOR / AKT

690693 (GlaxoSmithKline)
Afinitor; everolimus (Novartis)
AZD-6244 (AstraZeneca)
AZD8055 (AstraZeneca)
BEZ-235 Novartis
BGT-226 (Novartis)
MK-2206 (Merck)
ridaforolimus; deforolimus; MK-8806; AP-23573 (Merck / Ariad)
XL-147, XL-765 (Exelixis / Sanofi-Aventis)

WT1

Antigen Specific WT1; (GlaxoSmithKline)

Table of Contents

Table of Contents.....	2
Executive Summary.....	4
Top-Ten Report Highlights.....	6
<u>Breast Cancer Unmet Needs</u>	6
<u>Angiogenesis inhibitors</u>	7
<u>Antimitotics: Taxane / Epothilone / Vinca / 5FU9</u>	
<u>Antiresorptives</u>	10
<u>GPNMB</u>	10
<u>HER2</u>	11
<u>HER2 / EGFR</u>	14
<u>IGF-1</u>	15
<u>PARP</u>	16
<u>PI3K / RAS / mTOR / AKT / MEK18</u>	
Key Findings.....	21
Breast Cancer Unmet Needs.....	21
<u>High Risk Adjuvant</u>	21
<u>1st-line Metastatic Breast Cancer</u>	23
<u>2nd-line / 3rd-line / Salvage Metastatic Breast Cancer</u>	24
<u>Estrogen Receptor Positive</u>	25
<u>Triple Negative</u>	26
<u>Genomics / Biomarkers</u>	28
Pharmacotherapies (Alphabetical by Target).....	29
<u>Angiogenesis inhibitors</u>	29
Avastin; bevacizumab (Genentech).....	29
Nexavar; sorafenib (Bayer-Schering/Onyx).....	31
Sutent; sunitinib (Pfizer).....	35
<u>Antimitotics: Taxane / Epothilone / Vinca / 5FU36</u>	
Abraxane; nab-paclitaxel (Abraxis).....	36
eribulin; E7389 (Eisai).....	37
Ixempra; ixabepilone (Bristol-Myers Squibb).....	38
Xeloda; capecitabine (Roche).....	38
Xyotax; a.k.a. Opaxio (Cell Therapeutics).....	39
<u>Antiresorptives</u>	41
Prolia; denosumab (Amgen), Zometa; zoledronic acid (Novartis); Bonfos; clodronate (Bayer-Schering).....	41
<u>Bcl2</u>	43
ABT-737 (Abbott).....	43
<u>GPNMB</u>	44
CDX-011; CR011-vcMMAE (Celldex).....	44
<u>HER2</u>	45
Herceptin; trastuzumab (Genentech).....	45
Omnitarg; pertuzumab (Genentech).....	48
trastuzumab-DM1; T-DM1 (Genentech / ImmunoGen).....	48
<u>HER2 / EGFR</u>	55

Tykerb; lapatinib (GlaxoSmithKline).....	55
neratinib; HKI-272 (Pfizer).....	58
HER3 60	
MM-121 (Sanofi-Aventis / Merrimack).....	60
Hormonal Therapy 61	
Aromasin; exemestane (Pfizer), Femara; letrozole (Novartis).....	61
IGF1 61	
AMG 479 (Amgen).....	62
dalotuzumab; MK-0646 (Merck).....	62
figitumumab; CP-751871 (Pfizer).....	66
PARP 67	
olaparib; AZD2281 (AstraZeneca), ABT-888 (Abbott), MK-4827 (Merck), AG014699 (Pfizer).....	69
BSI-201 (BiPar Sciences / Sanofi-Aventis).....	71
MK-4827 (Merck), AG014699 (Pfizer).....	77
PI3K / RAS / mTOR / AKT / MEK77	
690693; AKT (GlaxoSmithKline).....	80
Afinitor; everolimus (Novartis).....	80
BEZ-235, BGT-226 (Novartis).....	84
MK-2206 (Merck) / AZD6244 (AstraZeneca).....	86
ridaforolimus; deforolimus; MK-8806; AP-23573 (Merck / Ariad).....	86
XL-147, XL-765 (Exelixis / Sanofi-Aventis).....	87
WT1 88	
Antigen Specific WT1; GlaxoSmithKline.....	88
Thought Leader Interviews	89
Interview OHIID02395	89
Interview OHIID02396	98
Interview OHIID02397	109
Interview OHIID02398	117
Interview OHIID02399	123
Interview OHIID02400	133